XML 32 R19.htm IDEA: XBRL DOCUMENT
v3.21.2

Equity Incentive Plan | 3 Months Ended
--- | ---
Sep. 30, 2021
Equity Incentive Plan |
Equity Incentive Plan | 13. Equity Incentive Plan Aytu 2015 Plan. On June 1, 2015, the Company’s stockholders approved the Aytu BioPharma 2015 Stock Option and Incentive Plan (the “Aytu 2015 Plan”), which, as amended in July 2017, provides for the award of stock options, stock appreciation rights, restricted stock and other equity awards for up to an aggregate of 3.0 million shares of common stock. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by Aytu prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2015 Plan will be added back to the shares of common stock available for issuance under the Aytu 2015 Plan. On February 13, 2020, the Company’s stockholders approved an increase to 5.0 million total shares of common stock in the Aytu 2015 Plan. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 3 to 4 years. The restricted stock awards have a vesting period ranging from 4 to 10 years, whereas the restricted stock units have a vesting period 4 years. As of September 30, 2021, the Company had 2,792,139 shares that are available for grant under the Aytu 2015 Plan. Neos 2015 Plan. Pursuant to the Neos Merger, the Company assumed 69,721 stock options and 35,728 restricted stock units (RSUs) previously granted under Neos plan. Accordingly, on April 19, 2021, the Company registered 105,449 shares of its common stock under the Neos Therapeutics, Inc. 2015 Stock Options and Incentive Plan (the "Neos 2015 Plan") with the SEC. The terms and conditions of the assumed equity securities will stay the same as they were under the previous Neos plan. In addition to the 105,449 registered shares to cover the assumed awards, the remaining 1,255,310 shares available under the legacy Neos plan was added back to the new Neos 2015 Plan. The Company allocated costs of the replacement awards attributable to pre- and post-combination service periods. The pre-combination service costs were included in the considerations transferred. The remaining costs attributable to the post-combination service period are being recognized as stock-based compensation expense over the remaining terms of the replacement awards. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 1 to 4 years. As of September 30, 2021, the Company had 1,281,696 shares that are available for grant under the Neos 2015 Plan. Stock Options Stock option activity is as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  |  |  | ​ | ​ |  | Weighted
​ | ​ | ​ | ​ | ​ | ​ | ​ | Average
​ | ​ | ​ | ​ | Weighted | ​ | Remaining
​ | ​ | Number of | ​ | Average | ​ | Contractual
​ | ​ | Options | ​ | Exercise Price | ​ | Life in Years
Outstanding June 30, 2021 |  | 109,588 | ​ | $ | 14.52 |  | 8.07
Forfeited/Cancelled |  | (6,077) | ​ | ​ | 6.33 |  |
Expired |  | (7,645) | ​ | ​ | 8.53 |  |
Outstanding at September 30, 2021 |  | 95,866 | ​ | $ | 15.52 |  | 8.40
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Exercisable at September 30, 2021 |  | 47,953 | ​ | $ | 22.73 |  | 8.28
​ As of September 30, 2021, there was $0.3 million of total unrecognized compensation costs adjusted for any estimated forfeitures, related to non-vested stock options granted under the Company’s equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 2.2 years. Restricted Stock On August 2, 2021, the Company granted 220,000 shares of restricted stock, with certain accelerated vesting conditions, to a member of its management pursuant to the Aytu 2015 Plan, of which 1/3 vest on August 2, 2022 and 1/12 on the first day of each quarter thereafter, subject to continuing employment with the Company through each vesting date until August 2, 2024. These restricted stocks grants have a grant date fair value of $4.02 per-share. Restricted stock activity is as follows: ​
​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Weighted
​ | ​ | ​ | ​ | Average Grant
​ | ​ | Number of | ​ | Date Fair
​ | ​ | Shares | ​ | Value
Unvested at June 30, 2021 |  | 1,955,268 | ​ | $ | 7.83
Granted |  | 220,000 | ​ | ​ | 4.02
Vested |  | (69,590) | ​ | ​ | 6.93
Unvested at September 30, 2021 |  | 2,105,678 | ​ | $ | 7.46
​ As of September 30, 2021, there was $12.9 million of total unrecognized compensation costs adjusted for any estimated forfeitures, related to non-vested restricted stock granted under the Company’s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of 3.3 years. The Company previously issued 158 shares of restricted stock outside the Aytu 2015 Plan, which vest in July 2026. The unrecognized expense related to these shares was $1.0 million as of September 30, 2021 and is expected to be recognized over the weighted average period of 4.8 years. Restricted Stock Unit Restricted stock unit activity is as follows: ​
​ | ​ | ​ | ​ | ​ | ​
​ |  |  |  | ​ | ​
​ | ​ | ​ | ​ | Weighted
​ | ​ | ​ | ​ | Average Grant
​ | ​ | Number of | ​ | Date Fair
​ | ​ | Shares | ​ | Value
Unvested at June 30, 2021 |  | 78,318 | ​ | $ | 7.20
Forfeited | ​ | (1,156) | ​ | ​ | 6.12
Unvested at September 30, 2021 |  | 77,162 | ​ | $ | 7.21
​ As of September 30, 2021, there was $0.4 million of total unrecognized compensation costs adjusted for any estimated forfeitures, related to non-vested RSUs granted under the Company’s equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 2.2 years. Stock-based compensation expense related to the fair value of stock options and restricted stock and RSUs was included in the statements of operations as set forth in the below table: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended
​ | ​ | September 30,
​ | ​ | 2021 |  | 2020
​ | ​ | (In thousands)
Cost of sales | ​ | $ | 9 | ​ | $ | —
Research and development | ​ | ​ | 319 | ​ | ​ | —
Selling and marketing | ​ | ​ | 9 | ​ | ​ | —
General and Administrative | ​ |  | 1,182 | ​ |  | 455
Total stock-based compensation expense | ​ | $ | 1,519 | ​ | $ | 455
​ The stock-based compensation expense included in the table above is attributable to stock options and restricted stock of $23,000 and $1.5 million, respectively, for the three months ended September 30, 2021. The stock-based compensation expense included in the table above is attributable to stock options and restricted stock of $7,000 and $0.4 million, respectively, for the three months ended September 30, 2020.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration